Graham Richard A's Form 4 filing
Theravance Biopharma, Inc. (TBPH) · filed Nov 16, 2023
- Accession no.
- 0001415889-23-015228
- Filed
- Nov 16, 2023
- Trade date
- Nov 14, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $25.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Graham Richard ACIK 0001820036 | Officer (SVP, RESEARCH & DEVELOPMENT) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2023 | Ordinary Shares | SSaleDisposed | −2,482 | $10.22 | −$25,366.04 | 346,839 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.